证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 投资者关系活动记录表 编号：2025-002 | 投资者关系活动类别 | ☐特定对象调研 | ☐分析师会议 | | --- | --- | --- | | | ☐媒体采访 | 业绩说明会 | | | ☐新闻发布会 | ☐路演活动 | | | ☐现场参观 | | | | ☐其他（请文字说明其他活动内容） | | | 参与单位名称及人员姓名 | 线上参与公司2024年度业绩说明会的投资者 | | | 时间 | 2025年05月14日 15:00-17:00 | | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 上市公司接待人员姓名 | 董事长 葛建利 | | | | 董事、总经理 卢刚 | | | | 独立董事 俞毅 | | | | 独立董事 汪萍 | | | | 独立董事 崔孙良 | | | | 董事会秘书、副总经理 杨晓静 | | | | 财务总监 费超 | | | | 保荐代表人 杨科 | | 9.葛总你好，创新药是未来医药企业的发展必然趋势和选择，但 创新药耗时长、投资大，请问葛总如何兼 ...

Core Viewpoint - The company is focused on expanding its CDMO services and developing innovative biopharmaceuticals, with significant investments in R&D and strategic partnerships to enhance its product offerings and market presence [1][6][7]. Company Overview - The company provides key pharmaceutical intermediates and raw material CDMO services to multinational pharmaceutical companies and research institutions, with a focus on various therapeutic areas including antiviral, oncology, and cardiovascular diseases [1][2]. - The company has established a subsidiary, Jiuqian Cheng Bio, to enter the biopharmaceutical sector, particularly in cell therapy [4][6]. R&D Investment - The company invested CNY 93.71 million in R&D, accounting for 28.13% of its revenue, representing a 241.20% increase year-on-year [5]. - The company has developed several advanced technology platforms for drug synthesis and is enhancing its capabilities in high-end raw material and formulation development [5]. Market Expansion - The company is actively developing its market presence by participating in major industry exhibitions and strengthening relationships with international pharmaceutical companies [7]. - The company aims to become a significant small molecule CDMO service provider in China, offering comprehensive lifecycle services to global innovative drug clients [7]. Talent Development - The company has a workforce of 607 employees, with a significant proportion holding advanced degrees, and has increased its R&D personnel by 36.26% [9]. - The company emphasizes a comprehensive training system to enhance employee skills and support its strategic goals [9]. Project Investment - The company is upgrading its production facilities to improve efficiency and reduce costs, with new projects expected to add 519,000 liters of production capacity [10]. - The company is also focusing on energy-saving technologies and green production methods to enhance sustainability [10]. Quality Management - The company has undergone 26 quality audits and has maintained compliance with various regulatory inspections, ensuring a robust quality management system [10][11]. - The company has integrated safety and environmental management into its core operations, receiving recognition for its green development initiatives [11]. Strategic Partnerships - The company has entered into a collaboration with Chiron Pharma for cell therapy projects, with a total project value of USD 17 million, focusing on heart and brain stroke treatments [6][13]. - The projects have received FDA clinical approvals, with ongoing clinical trials in the U.S. and plans for implementation in China [6][13][14].